IsoPlexis to Report Second Quarter 2022 Financial Results on August 10, 2022

BRANFORD, Conn., July 21, 2022 (GLOBE NEWSWIRE) — IsoPlexis Corporation (Nasdaq: ISO), the Superhuman Cell Company, today announced it will report financial results for the second quarter 2022 before market open on Wednesday, August 10, 2022. Company management will be webcasting a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time.

Live audio of the webcast will be available on the “Investors” section of the company website at: www.isoplexis.com. The webcast will be archived and available for replay after the event.

About IsoPlexis

IsoPlexis is the Superhuman Cell company.

By leading the discovery and identification of how multi-functional immune— Superhuman— cells communicate and respond, IsoPlexis assists researchers in understanding and predicting disease progression, treatment resistance and therapeutic efficacy.

IsoPlexis has been named Top Innovation or Design by The Scientist Magazine, Fierce, BIG Innovation, Red Dot and multiple others. The IsoPlexis platform is used globally by researchers, including those at the top 15 global pharmaceutical companies by revenue and at over 70% of leading U.S. comprehensive cancer centers.

Investor Contact
investors@isoplexis.com

Press Contact
press@isoplexis.com

Staff

Recent Posts

MEDITECH Announces the Passing of Founder and Chairman A. Neil Pappalardo

Reflections on his 56-year legacy as a tech pioneer and founder of the EHR industryCANTON,…

1 hour ago

eClinicalWorks and Sunoh.ai Assist Healthy Horizons Clinic Save Over Two Hours Daily on Clinical Documentation

Multispecialty practice transforms patient care, improves operational efficiency, and increases patient engagement with AI medical…

1 hour ago

TRNR Publishes Comprehensive Sportstech Documentation for Shareholders

Timeline and Source Materials Now Available at interactivestrength.com/sportstech AUSTIN, TEXAS / ACCESS Newswire / January…

1 hour ago

KORU Medical Systems Receives FDA 510(k) Clearance for Delivery of RYSTIGGO® (rozanolixizumab-noli), Expanding Label for FreedomEDGE® Infusion System

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading…

4 hours ago

Hologic Announces Financial Results for First Quarter of Fiscal 2026

– Revenue of $1,047.8 Million Grows 2.5% – – GAAP Diluted EPS of $0.79 Decreases…

4 hours ago

Illumina completes acquisition of SomaLogic

Deeply expands leadership in proteomics and multiomicsCombined capabilities bring high scalability, flexibility, and affordability into protein…

4 hours ago